Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study

BACKGROUND: Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:EBioMedicine
Main Authors: Ruck, Tobias, Schulte-Mecklenbeck, Andreas, Pfeuffer, Steffen, Heming, Michael, Klotz, Luisa, Windhagen, Susanne, Kleinschnitz, Christoph, Gross, Catharina C., Wiendl, Heinz, Meuth, Sven G.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Research paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6711888/
https://ncbi.nlm.nih.gov/pubmed/31371192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.062
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares